ResMed (NYSE:RMD – Get Free Report) had its price objective increased by equities researchers at Wells Fargo & Company from $215.00 to $250.00 in a research report issued to clients and investors on Friday, Benzinga reports. The firm currently has an “equal weight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price objective would indicate a potential upside of 7.79% from the company’s previous close.
Several other analysts have also issued reports on RMD. Jefferies Financial Group cut their target price on ResMed from $240.00 to $225.00 and set a “hold” rating for the company in a research note on Friday, July 10th. Mizuho set a $270.00 price target on ResMed in a research report on Friday. Weiss Ratings upgraded shares of ResMed from a “hold (c)” rating to a “hold (c+)” rating in a report on Thursday, October 8th. Royal Bank Of Canada raised their price target on ResMed from $262.00 to $288.00 and gave the company an “outperform” rating in a report on Friday. Finally, Rothschild & Co Redburn assumed coverage on ResMed in a research report on Wednesday, August 19th. They set a “neutral” rating and a $230.00 price objective on the stock. Seven analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $251.00.
Check Out Our Latest Research Report on RMD
ResMed Stock Performance
Shares of ResMed stock traded down $20.89 during mid-day trading on Friday, hitting $231.94. 1,650,374 shares of the stock were exchanged, compared to its average volume of 1,293,578. ResMed has a 12 month low of $180.26 and a 12 month high of $277.67. The company has a market capitalization of $32.62 billion, a P/E ratio of 22.23, a P/E/G ratio of 1.53 and a beta of 0.75. The company has a 50-day simple moving average of $231.83 and a 200 day simple moving average of $225.57. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.42 and a current ratio of 3.10.
ResMed (NYSE:RMD – Get Free Report) last posted its quarterly earnings results on Thursday, October 29th. The medical equipment provider reported $2.91 earnings per share for the quarter, topping the consensus estimate of $2.67 by $0.24. ResMed had a return on equity of 25.58% and a net margin of 26.94%. The company had revenue of $1.41 billion during the quarter, compared to the consensus estimate of $1.39 billion. During the same quarter in the prior year, the company earned $2.55 EPS. The firm’s quarterly revenue was up 5.9% compared to the same quarter last year. Sell-side analysts anticipate that ResMed will post 12.11 earnings per share for the current fiscal year.
Insider Activity
In related news, Director Peter Farrell sold 970 shares of the stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $234.73, for a total value of $227,688.10. Following the completion of the transaction, the director owned 51,803 shares of the company’s stock, valued at approximately $12,159,718.19. This trade represents a 1.84% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Michael Farrell sold 4,991 shares of ResMed stock in a transaction that occurred on Wednesday, October 7th. The stock was sold at an average price of $226.33, for a total value of $1,129,613.03. Following the completion of the transaction, the chief executive officer owned 479,803 shares of the company’s stock, valued at approximately $108,593,812.99. This trade represents a 1.03% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 24,343 shares of company stock worth $5,396,098. 0.58% of the stock is currently owned by corporate insiders.
Institutional Trading of ResMed
Several institutional investors have recently added to or reduced their stakes in RMD. BlackRock Inc. purchased a new stake in shares of ResMed in the second quarter worth approximately $2,400,375,000. State Street Corp boosted its holdings in ResMed by 0.6% during the 2nd quarter. State Street Corp now owns 6,680,735 shares of the medical equipment provider’s stock valued at $1,301,942,000 after acquiring an additional 37,567 shares during the period. Bank of New York Mellon Corp grew its position in ResMed by 0.7% in the 1st quarter. Bank of New York Mellon Corp now owns 4,925,386 shares of the medical equipment provider’s stock valued at $1,105,651,000 after acquiring an additional 34,732 shares during the last quarter. First Trust Advisors LP increased its stake in ResMed by 1.3% in the first quarter. First Trust Advisors LP now owns 1,537,825 shares of the medical equipment provider’s stock worth $345,211,000 after purchasing an additional 20,233 shares during the period. Finally, Swedbank AB increased its stake in ResMed by 22.5% in the first quarter. Swedbank AB now owns 1,350,234 shares of the medical equipment provider’s stock worth $303,101,000 after purchasing an additional 247,758 shares during the period. Institutional investors own 54.98% of the company’s stock.
Key ResMed News
Here are the key news stories impacting ResMed this week:
- Positive Sentiment: ResMed reported adjusted earnings of $2.91 per share, well above the $2.67 analyst consensus and up from $2.55 a year earlier. Revenue increased 5.9% year over year to $1.41 billion, also exceeding estimates of $1.39 billion. ResMed Beats Q1 Earnings and Revenue Estimates
- Positive Sentiment: Sustained demand for sleep devices, productivity improvements and gross-margin expansion supported the quarterly performance, providing evidence that ResMed continues to convert sales growth into stronger profitability. RMD Stock Up on Q1 Earnings and Revenue Beat
- Positive Sentiment: The company declared a quarterly dividend of $0.66 per share, or $2.64 annually, reinforcing its shareholder-return profile. The dividend yield is approximately 1.1%. ResMed Dividend Information
- Neutral Sentiment: KeyCorp raised its price target from $267 to $277 and maintained an Overweight rating, implying substantial potential upside based on the cited share price. However, the target is an analyst opinion rather than a change to company guidance. KeyCorp Raises ResMed Price Target
- Negative Sentiment: RMD’s decline following the earnings release suggests the stronger-than-expected results were already reflected in the stock or that investors wanted faster growth or more upbeat forward commentary. The roughly 6% revenue increase remains healthy but may have appeared less compelling relative to the company’s valuation.
ResMed Company Profile
ResMed Inc is a medical equipment and software company that develops solutions for sleep-disordered breathing, respiratory conditions and other chronic diseases. The company is best known for its positive airway pressure (PAP) devices used to treat obstructive sleep apnea, along with masks, accessories and related patient support services.
ResMed also provides cloud-connected health technology, including remote-monitoring platforms and software used by healthcare providers, medical equipment suppliers and care organizations.
Featured Articles
- Five stocks we like better than ResMed
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for ResMed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed and related companies with MarketBeat.com's FREE daily email newsletter.
